The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial

This multicenter study is looking at the prognostic value of measuring a specific type of cell (circulating plasma cells, or CPCs) in the blood of newly diagnosed multiple myeloma patients, using a technique called flow cytometry, to better predict how the disease will progress. **You may be eligible if...** - You have been newly diagnosed with multiple myeloma - You have not yet received any treatment for multiple myeloma - You are between 18 and 80 years old - You have no prior history of other cancers **You may NOT be eligible if...** - You have already received treatment for myeloma - You have a related but different condition (such as smoldering myeloma, MGUS, plasma cell leukemia, amyloidosis, or Waldenström's macroglobulinemia) - You have an active infection - You are HIV positive - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.